COPENHAGEN, Denmark, Aug. 27, 2025 – Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor conferences in September:
- Citi 2025 Biopharma Back-to-School Conference
Format: 1×1 meetings
Date: Tuesday, September 2, 2025
Location: Boston, MA - Wells Fargo 2025 Healthcare Conference
Format: Company presentation
Date: Wednesday, September 3, 2025
Time: 3:45 p.m. ET
Location: Boston, MA - Cantor Global Healthcare Conference
Format: 1×1 meetings
Date: Thursday, September 4, 2025
Location: New York, NY - Morgan Stanley 23rd Annual Global Healthcare Conference
Format: Company presentation
Date: Monday, September 8, 2025
Time: 1:50 p.m. ET
Location: New York, NY - Bank of America Healthcare Trailblazers Private Company Conference
Format: 1×1 meetings
Date: Wednesday, September 17, 2025
Location: Boston, MA
About Adcendo
Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. Led by a team of industry veterans with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies. For further information, please visit www.adcendo.com or follow the company on LinkedIn.
For further information:
Argot Partners
Tel: +1 (212) 600-1494
E-mail: adcendo@argotpartners.com
Adcendo ApS
Email: info@adcendo.com